DE60305167D1 - Verwendung von l-alpha lipophosphatidylcholine zur in vitro differenzierung von monocyten in reifen dendritische zellen - Google Patents

Verwendung von l-alpha lipophosphatidylcholine zur in vitro differenzierung von monocyten in reifen dendritische zellen

Info

Publication number
DE60305167D1
DE60305167D1 DE60305167T DE60305167T DE60305167D1 DE 60305167 D1 DE60305167 D1 DE 60305167D1 DE 60305167 T DE60305167 T DE 60305167T DE 60305167 T DE60305167 T DE 60305167T DE 60305167 D1 DE60305167 D1 DE 60305167D1
Authority
DE
Germany
Prior art keywords
dendritic cells
monocytes
agent
alpha
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60305167T
Other languages
English (en)
Other versions
DE60305167T2 (de
Inventor
Vincent Lotteau
Patrice Andre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Biomerieux SA
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0203499A external-priority patent/FR2836828A1/fr
Application filed by Biomerieux SA, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Biomerieux SA
Application granted granted Critical
Publication of DE60305167D1 publication Critical patent/DE60305167D1/de
Publication of DE60305167T2 publication Critical patent/DE60305167T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60305167T 2002-03-11 2003-03-07 Verwendung von l-alpha lysophosphatidylcholine zur in vitro differenzierung von monocyten in reifen dendritischen zellen Expired - Lifetime DE60305167T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0203499A FR2836828A1 (fr) 2002-03-11 2002-03-11 Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro
FR0203499 2002-03-11
FR0301063A FR2836829B1 (fr) 2002-03-11 2003-01-30 Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro
FR0301063 2003-01-30
PCT/FR2003/000741 WO2003076602A2 (fr) 2002-03-11 2003-03-07 Siomerieux s.a. - inserm

Publications (2)

Publication Number Publication Date
DE60305167D1 true DE60305167D1 (de) 2006-06-14
DE60305167T2 DE60305167T2 (de) 2007-05-31

Family

ID=27767084

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60305167T Expired - Lifetime DE60305167T2 (de) 2002-03-11 2003-03-07 Verwendung von l-alpha lysophosphatidylcholine zur in vitro differenzierung von monocyten in reifen dendritischen zellen

Country Status (9)

Country Link
US (3) US7368287B2 (de)
EP (2) EP1483374B1 (de)
JP (1) JP4482683B2 (de)
AT (1) ATE325866T1 (de)
AU (1) AU2003227822A1 (de)
DE (1) DE60305167T2 (de)
ES (1) ES2262994T3 (de)
FR (1) FR2836829B1 (de)
WO (1) WO2003076602A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101951933B1 (ko) * 2013-03-12 2019-02-25 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
CN113908296A (zh) * 2013-09-26 2022-01-11 新加坡国立大学 利用溶血磷脂酰胆碱支架的组合物和方法
EP3000471A1 (de) * 2014-09-28 2016-03-30 Bernhard-Nocht-Institut für Tropenmedizin Neue immunstimulierende Moleküle
JP6652264B2 (ja) * 2015-09-29 2020-02-19 国立大学法人大阪大学 白血球浸潤促進剤および腫瘍免疫活性化剤
KR101862502B1 (ko) * 2017-01-02 2018-05-29 성균관대학교산학협력단 재구성 인공 암세포, 이의 제조 방법, 및 이를 포함하는 항암 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US4746652A (en) * 1986-11-18 1988-05-24 Wake Forest University Method of inducing diuresis with lysophospholipids
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
CA2090738C (en) * 1993-02-24 1996-05-21 Hema-Quebec Use of paf
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
FR2826975B1 (fr) * 2001-07-09 2004-06-04 Bio Merieux Utilisation de lipoproteines oxydees pour obtenir la differenciation de monocytes en cellules dendritiques matures

Also Published As

Publication number Publication date
AU2003227822A1 (en) 2003-09-22
DE60305167T2 (de) 2007-05-31
FR2836829A1 (fr) 2003-09-12
ATE325866T1 (de) 2006-06-15
EP1483374B1 (de) 2006-05-10
FR2836829B1 (fr) 2005-11-25
WO2003076602A3 (fr) 2004-04-08
WO2003076602A2 (fr) 2003-09-18
US20080176820A1 (en) 2008-07-24
EP1666039A1 (de) 2006-06-07
AU2003227822A8 (en) 2003-09-22
US7368287B2 (en) 2008-05-06
US20050054095A1 (en) 2005-03-10
JP4482683B2 (ja) 2010-06-16
EP1483374A2 (de) 2004-12-08
US20110135684A1 (en) 2011-06-09
JP2005530488A (ja) 2005-10-13
ES2262994T3 (es) 2006-12-01

Similar Documents

Publication Publication Date Title
Locati et al. Diversity, mechanisms, and significance of macrophage plasticity
Castellana et al. Macrophages contribute to the cyclic activation of adult hair follicle stem cells
Manicassamy et al. Toll-like receptor 2–dependent induction of vitamin A–metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity
Terhorst et al. Dynamics and transcriptomics of skin dendritic cells and macrophages in an imiquimod-induced, biphasic mouse model of psoriasis
Neumann et al. Production of a macrophage growth factor (s) by a goldfish macrophage cell line and macrophages derived from goldfish kidney leukocytes
Unanue Secretory function of mononuclear phagocytes: a review.
Müller et al. Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms?
Kissenpfennig et al. Langerhans cells–revisiting the paradigm using genetically engineered mice
Smith et al. Isolation and purification of CD14-negative mucosal macrophages from normal human small intestine
Galvin et al. Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells
Chia et al. Dendritic cells maintain dermal adipose–derived stromal cells in skin fibrosis
Kavian et al. Arsenic trioxide prevents murine sclerodermatous graft-versus-host disease
Gajardo et al. Exogenous interleukin‐33 targets myeloid‐derived suppressor cells and generates periphery‐induced Foxp3+ regulatory T cells in skin‐transplanted mice
Chen et al. Follicular helper T cells promote liver pathology in mice during Schistosoma japonicum infection
Rani et al. Burn wound γδ T-cells support a Th2 and Th17 immune response
Brain et al. Biologic potential of pulmonary macrophages
JP2022541572A (ja) 創傷治癒のためのｙａｐ阻害
Coomes et al. Pleiotropic effects of transforming growth factor-β in hematopoietic stem-cell transplantation
Tijaro-Ovalle et al. Metabolic targets for improvement of allogeneic hematopoietic stem cell transplantation and graft-vs.-host disease
Neuringer et al. Obliterative bronchiolitis or chronic lung allograft rejection: a basic science review
Collins et al. Sustained accumulation of antigen‐presenting cells after infection promotes local T‐cell immunity
DE60305167D1 (de) Verwendung von l-alpha lipophosphatidylcholine zur in vitro differenzierung von monocyten in reifen dendritische zellen
Akaza et al. Effects of Propionibacterium acnes on various mRNA expression levels in normal human epidermal keratinocytes in vitro
Tajpara et al. Epicutaneous administration of the pattern recognition receptor agonist polyinosinic–polycytidylic acid activates the MDA5/MAVS pathway in Langerhans cells
Huber et al. Management of refractory early-stage cutaneous T-cell lymphoma

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition